Several reports sharpen the stewardship and diagnostics agenda. A market-access critique argued that antibiotic development is not the limiting factor—delivery and access are. In parallel, a narrative review emphasized that most penicillin allergy labels are wrong and that PEN-FAST plus direct oral challenge can enable routine delabeling, reducing unnecessary avoidance. In diagnostics, a new study assessed a cloning-based 16S rDNA PCR library workflow for polymicrobial bloodstream infections, detecting more pathogens than blood culture while maintaining better agreement with culture than direct high-throughput sequencing. The results are particularly relevant for bloodstream infections where culture negativity and polymicrobial mixtures complicate therapy. Finally, a study on vaccination and antibiotic use found vaccination programs reduce antibiotic consumption and drug-resistant infections in a global scoping review, positioning immunization as an upstream antimicrobial stewardship lever. For biotech and pharma, the cluster points to near-term commercial opportunities beyond new molecules: improving testing accuracy, shortening time-to-pathogen understanding, and reducing unnecessary antibiotic exposure through label correction and prevention-linked stewardship.